GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

Chongkundang Holdings 001630.KS · KRW

Health Care · KRX · 🇰🇷 South Korea

Compare

36,000

+0.28%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Chongkundang Holdings

Its shares trade on KRX under the ticker 001630.KS. It has been listed since 30 June 1976. In the fiscal year to 31 December 2025, it reported revenue of ₩959.01bn and net income of ₩40.43bn. At that date it held total assets of ₩1.63trn and shareholders' equity of ₩637.02bn.

ChongKunDang Holdings Corp. is a business development and investment company, which focuses on pharmaceutical operations. The company is headquartered in Seoul, Seoul. Through its subsidiary, the Company provides pharmaceuticals, including remedies for high blood pressure and high cholesterol, immunosuppressive drugs, antitumor agents, antibiotics, remedies for erectile dysfunction and remedies for obesity. The company also produces antitumor agents, antibiotics, digestives, circulation agents, respiratory agents, remedies for endocrine diseases, remedies for skin diseases, functional cosmetics and others, as well as pharmaceutical ingredients. On November 2, 2013, the Company divested its pharmaceutical business into a newly established wholly owned subsidiary. After the divestiture, the Company engages in the investment and holding business.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
30 Jun 1976

Leadership

Pay as last reported

  • Mr. Jang Han LeeChairman, since 2021₩1.77bn
  • Mr. Tae Yeong KimChief Executive Officer, Vice President, Director, since 2006
  • Mr. Jang Won ChoiManaging Director, since 2019
  • Mr. Gi Seong LeeManaging Director
  • Mr. Seong Wuk HanManaging Director, since 2023
  • Mr. Yun Han LeeManaging Director, since 2021
  • Mr. Jung Yong ChoInternal Auditor
  • Mr. Hui Nam ChoiDirector
  • Mr. Hui Jae LeeDirector
  • Mr. Jeong Hui ChoNon-Executive Independent Director
  • Mr. Seung Yong NahNon-Executive Independent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Headquartered in Seoul, South Korea
  • Focus on pharmaceutical operations through subsidiaries
  • Divested pharmaceutical business into a wholly owned subsidiary in 2013

Weaknesses

  • Relies on investment and holding business after divesting pharmaceutical operations
  • No specific financial data provided for performance metrics
  • Limited detail on current business operations beyond divestiture

Opportunities

  • Potential growth in pharmaceutical investment opportunities
  • Expansion into new markets for pharmaceutical ingredients
  • Increased demand for specialized pharmaceutical products

Threats

  • Competition in the pharmaceutical investment sector
  • Regulatory challenges in the healthcare industry
  • Dependence on subsidiary performance for pharmaceutical operations

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.